Laboratory of Rare Lung Diseases

Denis Hadjiliadis, M.D., MHS

Denis Hadjiliadis, MD, MHSAssistant Professor of Medicine
Associate Medical Director, Lung Transplantation Program
University of Pennsylvania Medical Center 
Pulmonary, Allergy & Critical Care Division
835 West Gates Building
3600 Spruce Street 
Philadelphia, PA 19104

(215) 615-3871
(215) 662-3226
denis.hadjiliadis@uphs.upenn.edu

Education: 
M.D., University of Toronto, Toronto, Canada
Master of Health Sciences, Duke University, Durham, NC

Residency: 
Internal Medicine, Mayo Graduate School of Medicine, Rochester, MN

Fellowship:
Lung Transplantation and Cystic Fibrosis, University of Toronto, Toronto, Canada

Dr. Hadjiliadis is a member of the advanced lung disease team at the University of Pennsylvania. His main clinical interests include management of lung transplant recipients before and after lung transplantation, cystic fibrosis and respiratory problems in recipients of other organ transplants. His main research interests include chronic rejection after lung transplantation, gastroesophageal reflux disease in advanced lung disease and lung transplant patients, choice of transplant operation in patients with advanced lung disease, and predictions of outcome in patients with cystic fibrosis and lung transplantation. 

Selected publications

  1. Dekerlegand RL, Hadjiliadis D, Swisher AK, Parrott JS, Heuer AJ, Myslinski MJ. Inspiratory muscle strength relative to disease severity in adults with stable cystic fibrosis. J Cyst Fibros. 2015 May 21. pii: S1569-1993(15)00118-6. [Epub ahead of print]
  2. Turowski JB, Pietrofesa RA, Lawson JA, Christofidou-Solomidou M, Hadjiliadis D. Flaxseed modulates inflammatory and oxidative stress biomarkers in cystic fibrosis: a pilot study. 2015 May 13;15(1):148. [Epub ahead of print]
  3. Bucki R, Cruz K, Pogoda K, Eggert A, Chin L, Ferrin M, Imbesi G, Hadjiliadis D, Janmey PA. Enhancement of Pulmozyme activity in purulent sputum by combination with poly-aspartic acid or gelsolin. 2015 Feb 12. [Epub ahead of print]
  4. Sexauer WP, Hadeh A, Ohman-Strickland PA, Zanni RL, Varlotta L, Holsclaw D, Fiel S, Graff GR, Atlas A, Bisberg D, Hadjiliadis D, Michel SH, Mintz D, Chakraborty R, Marra B, Lomas P, Ward T, Sassman M, Imbesi GC, Kitch DM, Mallowe AM. Vitamin D deficiency is associated with pulmonary dysfunction in cystic fibrosis. 2015 Jan 7. [Epub ahead of print]
  5. Dorgan DJ, Hadjiliadis D. Lung transplantation in patients with cystic fibrosis: special focus to infection and comorbidities. Expert Expert Rev Respir Med. 2014 Jun;8(3):315-26.
  6. Ahluwalia M, Hoag JB, Hadeh A, Ferrin M, Hadjiliadis D. Cystic fibrosis and pregnancy in the modern era: A case control study. J Cyst Fibros. 2014 Jan;13(1):69-73.
  7. Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B; Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Am J Respir Crit Care Med. 2013 Apr;187(7):680-9.
  8. Colman RE, Curtis JR, Nelson JE, Efferen L, Hadjiliadis D, Levine DJ, Meyer KC, Padilla M, Strek M, Varkey B, Singer LG. Barriers to Optimal Palliative Care of Lung Transplant Candidates. Chest. 2012 Aug 20. doi: 10.1378/chest.12-0830.
  9. Hadjiliadis D. ACP Journal Club. Ivacaftor improved lung function in cystic fibrosis with G551D mutation.Ann Intern Med. 2012 Apr 17;156(8):JC4-10. No abstract available. 
  10. Kremer BE, Reshef R, Misleh JG, Christie JD, Ahya VN, Blumenthal NP, Kotloff RM, Hadjiliadis D, Stadtmauer EA, Schuster SJ, Tsai DE. Post-transplant lymphoproliferative disorder after lung transplantation: a review of 35 cases. J Heart Lung Transplant. 2012 Mar;31(3):296-304.
Top